Key Benefits

• Spot cancer-related inflammation burden using NLR, PLR, SII, and SIRI ratios.
• Flag imbalance between neutrophils, lymphocytes, platelets, and monocytes that tracks tumor activity.
• Clarify prognosis by linking higher ratios with worse outcomes in many cancers.
• Guide preoperative risk talks by identifying higher complication and recurrence risk.
• Support treatment monitoring by tracking inflammatory shifts during chemotherapy, immunotherapy, or radiation.
• Track trends over time to assess response and detect worsening inflammation early.
• Avoid using these ratios to diagnose cancer; they are nonspecific inflammation markers.
• Interpret best with a CBC differential, CRP, imaging, and your cancer details.

What are Cancer-Associated Inflammation biomarkers?

Cancer-associated inflammation biomarkers are blood signals that capture how a tumor and the immune system are talking. Cancer often stirs a body-wide inflammatory response that supports tumor growth and spread while straining normal tissues. Measuring these markers gives a real-time readout of that process, beyond what scans alone can show. Many come from the liver as part of the acute-phase response (C-reactive protein, serum amyloid A, fibrinogen), driven by immune messengers released by tumors and immune cells (interleukin-6, TNF-alpha, CXCL chemokines). Others reflect shifts in circulating blood cells mobilized by inflammation (neutrophils, lymphocytes; summarized in ratios like NLR). Some are enzymes and mediators tied to tissue remodeling and clotting (ferritin, lactate dehydrogenase, D-dimer). Together, they mirror the intensity and character of tumor-driven inflammation in the bloodstream, indicating how “hot” the cancer–host interaction is. Tracking them over time can reveal changes in disease activity, show whether treatment is damping inflammatory signaling, and help flag complications related to systemic inflammation.

Why is blood testing for Cancer-Associated Inflammation important?

Cancer-associated inflammation markers translate a routine blood count into a systems-level snapshot of immunity, coagulation, and stress biology. Ratios such as the neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio (PLR), and composites like the systemic immune‑inflammation index (SII) and systemic inflammation response index (SIRI) reflect how strongly innate, pro‑tumor inflammation is outweighing lymphocyte‑driven antitumor surveillance.In general populations, NLR often sits around 1–3, PLR around 100–200, SII roughly in the low hundreds, and SIRI around 0.3–1.0; study cut‑points vary by cancer and setting. For prognosis, values toward the lower end of these ranges are usually considered more favorable, while persistently higher values signal greater inflammatory and thrombotic activation.When these indices are low, they typically indicate preserved lymphocyte counts with modest neutrophil and platelet activity—a quieter inflammatory milieu that supports immune surveillance. If very low because neutrophils or platelets are depressed, that can reflect bone‑marrow suppression or viral illness, with symptoms like frequent infections, mouth sores, easy bruising, or heavier menstrual bleeding. Children naturally have lower NLRs (lymphocyte‑predominant), and pregnancy physiologically raises neutrophils, making very low ratios less common.When the indices are high, they point to neutrophilia, monocytosis, and thrombocytosis with relative lymphopenia—an environment linked to tumor growth, cachexia risk, and thrombosis, but also seen with acute infection, major stress, or corticosteroid exposure. People may notice fatigue, fevers, weight loss, or clotting events. Women tend to have slightly higher platelets, nudging PLR upward; pregnancy raises both neutrophils and platelets.Big picture: these markers knit together immunity, hemostasis, metabolism, and endocrine stress. They are not diagnostic but add prognostic context alongside CRP, ESR, albumin, and LDH, helping gauge trajectory, treatment tolerance, and long‑term risks across cancers and cardiovascular disease.

What insights will I get?

Cancer-Associated Inflammation blood testing provides insight into how your immune system and blood cells interact in the context of cancer risk and overall system health. Chronic inflammation can disrupt energy production, metabolism, cardiovascular function, and immune surveillance, all of which are critical for maintaining resilience against disease. At Superpower, we assess four key biomarkers—NLR (Neutrophil-to-Lymphocyte Ratio), PLR (Platelet-to-Lymphocyte Ratio), SII (Systemic Immune-Inflammation Index), and SIRI (Systemic Inflammation Response Index)—to give a comprehensive view of inflammation linked to cancer biology.NLR and PLR measure the balance between different types of white blood cells and platelets, reflecting how your body responds to stress and inflammation. SII and SIRI are composite indices that integrate neutrophil, lymphocyte, monocyte, and platelet counts, offering a broader picture of immune system activation and inflammatory status. Elevated values in these markers can signal a shift toward a pro-inflammatory state, which is associated with increased cancer risk and progression.Stable, healthy levels of NLR, PLR, SII, and SIRI suggest that your immune system is balanced and not chronically activated. This balance supports tissue repair, immune defense, and cellular stability, reducing the likelihood of inflammation-driven changes that can contribute to cancer development.Interpretation of these biomarkers can be influenced by factors such as acute infections, recent surgery, pregnancy, age, certain medications, and laboratory assay differences. These variables should be considered when evaluating results to ensure an accurate understanding of your inflammation status.